Jessie C Ziegler, Meera Heller, Sherry Cox, Joe S Smith
{"title":"Pharmacokinetics of Single Dose and Multidose Oral Gabapentin in Goats (Capra aegagrus hircus).","authors":"Jessie C Ziegler, Meera Heller, Sherry Cox, Joe S Smith","doi":"10.1111/jvp.70006","DOIUrl":null,"url":null,"abstract":"<p><p>There is a shifting public perception of animal welfare that has increased demand for establishing pain management strategies in livestock. Gabapentin is often utilized in practice to mitigate neuropathic pain. However, there is little pharmacokinetic information to guide its use in goats. The objectives of this study were to describe the pharmacokinetics of oral gabapentin in goats given as a single dose (SD) and multidose (MD) regimen, as well as to document any adverse effects after administration. Six healthy adult goats were administered 15 mg/kg of gabapentin orally once for the SD trial, and every 12 h for 6 doses for the MD trial. Plasma samples were collected and analyzed via reversed-phase high-performance liquid chromatography. After SD administration, maximum plasma concentration, time to maximum concentration, and elimination half-life were: 3.22 μg/mL; 4.49 h; and 8.15 h, respectively. After MD administration, maximum plasma concentration and time to maximum concentration were: 4.56 μg/mL and 2.24 h. Accumulation ratio (R) was 1.66 ± 0.81 when comparing the MD AUC12<sub>h</sub> to the SD AUC12<sub>h</sub>. Clinicians should be aware of the potential for increased accumulation ratio with multiple dosing strategies.</p>","PeriodicalId":17596,"journal":{"name":"Journal of veterinary pharmacology and therapeutics","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of veterinary pharmacology and therapeutics","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/jvp.70006","RegionNum":4,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
There is a shifting public perception of animal welfare that has increased demand for establishing pain management strategies in livestock. Gabapentin is often utilized in practice to mitigate neuropathic pain. However, there is little pharmacokinetic information to guide its use in goats. The objectives of this study were to describe the pharmacokinetics of oral gabapentin in goats given as a single dose (SD) and multidose (MD) regimen, as well as to document any adverse effects after administration. Six healthy adult goats were administered 15 mg/kg of gabapentin orally once for the SD trial, and every 12 h for 6 doses for the MD trial. Plasma samples were collected and analyzed via reversed-phase high-performance liquid chromatography. After SD administration, maximum plasma concentration, time to maximum concentration, and elimination half-life were: 3.22 μg/mL; 4.49 h; and 8.15 h, respectively. After MD administration, maximum plasma concentration and time to maximum concentration were: 4.56 μg/mL and 2.24 h. Accumulation ratio (R) was 1.66 ± 0.81 when comparing the MD AUC12h to the SD AUC12h. Clinicians should be aware of the potential for increased accumulation ratio with multiple dosing strategies.
期刊介绍:
The Journal of Veterinary Pharmacology and Therapeutics (JVPT) is an international journal devoted to the publication of scientific papers in the basic and clinical aspects of veterinary pharmacology and toxicology, whether the study is in vitro, in vivo, ex vivo or in silico. The Journal is a forum for recent scientific information and developments in the discipline of veterinary pharmacology, including toxicology and therapeutics. Studies that are entirely in vitro will not be considered within the scope of JVPT unless the study has direct relevance to the use of the drug (including toxicants and feed additives) in veterinary species, or that it can be clearly demonstrated that a similar outcome would be expected in vivo. These studies should consider approved or widely used veterinary drugs and/or drugs with broad applicability to veterinary species.